substance P (6-11)

C-terminal hexapeptide of substance P

Also Known As:

1-dearginyl-2,4-deprolyl-3-delysyl-5-deglutamine-substance P; 1-des-Arg-2,4-des-Pro-3-des-Lys-5-des-Gln-substance P; SP(6-11); SP6-11(C-terminal); pGlu SPH; sendide; substance P hexapeptide; substance P, dearginyl(1)-deprolyl(2,4)-delysyl(3)-deglutamine(5)-

Networked: 13 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Sethi, Tariq: 2 articles (01/2009 - 01/2003)
2.	Haslett, Christopher: 1 article (01/2009)
3.	MacKinnon, Alison C: 1 article (01/2009)
4.	Rossi, Adriano G: 1 article (01/2009)
5.	Seckl, Michael: 1 article (01/2009)
6.	Tufail-Hanif, Uzma: 1 article (01/2009)
7.	Wheatley, Mark: 1 article (01/2009)
8.	Nies, Michael: 1 article (06/2005)
9.	Ro, Jin Y: 1 article (06/2005)
10.	Zhang, Youping: 1 article (06/2005)

Related Diseases

1.	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/01/2003 - "[D-Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism." 10/01/2000 - "[Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) inhibits small cell lung cancer (SCLC) growth and is entering Phase II clinical investigation for the treatment of SCLC. " 06/01/1999 - "[Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism." 06/01/1999 - "[Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) (antagonist G) is a novel class of anti-cancer agent that inhibits small-cell lung cancer (SCLC) cell growth in vitro and in vivo and is entering phase II clinical investigation for the treatment of SCLC. " 05/26/1995 - "Processing of the neuropeptide growth factor antagonist [Arg6, D-Trp7.9, NmePhe8]-substance P (6-11) by a small cell lung cancer cell line (H69)."
2.	Edema (Dropsy) 06/14/2005 - "In order to study the contribution of endogenous SP in the MO-induced edema, groups of rats were pretreated with two different doses (100 nmol; 1 microl) of either peptidergic (Sendide) or non-peptidergic (L703, 606) neurokinin 1 (NK1) receptor antagonist in one masseter muscle 15 min prior to the MO injection in the same muscle. " 06/14/2005 - "Neither Sendide nor L703,606 pretreatment resulted in a significant inhibition of the MO-induced edema in the masseter muscle. "
3.	Neoplasms (Cancer) 01/01/2009 - "Targeting V1A-vasopressin receptors with [Arg6, D-Trp7,9, NmePhe8]-substance P (6-11) identifies a strategy to develop novel anti-cancer therapies." 06/01/1999 - "[Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) (antagonist G) is a novel class of anti-cancer agent that inhibits small-cell lung cancer (SCLC) cell growth in vitro and in vivo and is entering phase II clinical investigation for the treatment of SCLC. " 01/01/2009 - "The anti-cancer agent [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (SP-G) modulates gastrin releasing peptide (GRP) and arginine vasopressin signalling in small cell lung cancer cells leading to growth arrest and apoptosis. "
4.	Hyperalgesia 12/01/2004 - "The nitric oxide synthase (NOS) inhibitors (L-NNA, 20 mg/kg; L-NMMA, 30 mg/kg and AGUA, 50 mg/kg; i.p.), the SP antagonists (sendide and L-732,138, 100 microg/kg; i.v.) and the CGRP antagonist (hCGRP8-37, 100 microg/kg; i.v.) significantly attenuated the hyperalgesic activity and also reversed the potentiating effect of the BKB1- R agonist, DBK on diabetic hyperalgesia in STZ-mice. " 09/11/1999 - "A significant antagonistic effect of [D-Phe7, D-His9] substance P (6-11), a selective antagonist for substance P, was observed against the nociceptin-induced hyperalgesia. "
5.	Vomiting 12/11/1998 - "The frequency of cisplatin (10 mg/kg, i.p.)-induced retching (104.6 +/- 14.3/6 h) and vomiting (19.0 +/- 3.0/6 h) was significantly reduced by pretreatment with sendide (3.0 mg/kg, s.c.) (14.0 +/- 8.1/6 h and 1.8 +/- 1.2/6 h, respectively). " 12/11/1998 - "The antiemetic activity of sendide, a new peptide tachykinin NK1 receptor antagonist, against cisplatin-induced emesis was investigated using ferrets. "

Related Drugs and Biologics

1.	arginyl- tryptophyl- N- methylphenylalanyl- tryptophyl- leucyl- methioninamide
2.	Intercellular Signaling Peptides and Proteins (Growth Factors)
3.	Neuropeptides
4.	Oxidants (Oxidizing Agents)
5.	Substance P
6.	Gastrin-Releasing Peptide
7.	omega-N-Methylarginine (NG Monomethyl L Arginine)
8.	Nitric Oxide Synthase (NO Synthase)
9.	Neurokinin-1 Receptors (Neurokinin 1 Receptor)
10.	Tachykinins

Related Therapies and Procedures

1.	Therapeutics
2.	Spinal Injections